<DOC>
	<DOCNO>NCT00420186</DOCNO>
	<brief_summary>The purpose clinical research ass safety tolerability BMS-690514 give combination paclitaxel carboplatin . Paclitaxel carboplatin administer standard regimen every 3 week standard dos . BMS-690514 give interval escalate dos maximum tolerate dose ( MTD ) identify . An additional cohort subject treat BMS-690514 MTD combination Paclitaxel carboplatin</brief_summary>
	<brief_title>A Phase I Study BMS-690514 Combination With Paclitaxel Carboplatin</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Patients advance metastatic solid tumor paclitaxel/carboplatin consider appropriate therapy Centrally locate squamous cell carcinoma lung permit ECOG performance status 01 Life expectancy least 3 month Men woman age 18 Symptomatic brain metastasis . Patients sign symptom brain metastasis ineligible unless brain metastasis rule CT MRI Peripheral neuropathy ≥Grade 1 reason History thromboembolic disease bleeding diatheses within last 6 month Women child bear potential without adequate contraception , breastfeeding , pregnant Serious , uncontrolled medical disorder active infection Uncontrolled significant cardiac disease Uncontrolled hypertension ( 150/100 ) Allergy Cremophor EL®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>